CIBC Private Wealth Group LLC Cuts Stake in Allergan plc (AGN)
CIBC Private Wealth Group LLC trimmed its position in Allergan plc (NYSE:AGN) by 77.0% during the first quarter, HoldingsChannel.com reports. The firm owned 101,746 shares of the company’s stock after selling 340,439 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Allergan were worth $14,897,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Allergan by 2.9% in the 4th quarter. BlackRock Inc. now owns 21,466,017 shares of the company’s stock worth $2,869,149,000 after purchasing an additional 600,535 shares during the period. Oregon Public Employees Retirement Fund raised its holdings in shares of Allergan by 14,208.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 20,762,744 shares of the company’s stock worth $155,000 after purchasing an additional 20,617,639 shares during the period. Artisan Partners Limited Partnership raised its holdings in shares of Allergan by 6.5% in the 1st quarter. Artisan Partners Limited Partnership now owns 6,767,753 shares of the company’s stock worth $990,867,000 after purchasing an additional 410,746 shares during the period. Longview Partners Guernsey LTD raised its holdings in shares of Allergan by 288.6% during the 4th quarter. Longview Partners Guernsey LTD now owns 6,026,108 shares of the company’s stock valued at $805,450,000 after buying an additional 4,475,447 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Allergan by 27.6% during the 1st quarter. Janus Henderson Group PLC now owns 5,855,576 shares of the company’s stock valued at $857,312,000 after buying an additional 1,265,742 shares during the period. Institutional investors own 80.31% of the company’s stock.
In related news, Chairman Brent L. Saunders acquired 1,760 shares of Allergan stock in a transaction that occurred on Thursday, March 7th. The stock was acquired at an average price of $143.67 per share, for a total transaction of $252,859.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.08% of the company’s stock.
Shares of AGN opened at $121.91 on Friday. The company has a market capitalization of $40.13 billion, a PE ratio of 7.31, a PEG ratio of 1.12 and a beta of 1.32. The company has a quick ratio of 0.60, a current ratio of 0.71 and a debt-to-equity ratio of 0.32. Allergan plc has a 52 week low of $120.68 and a 52 week high of $197.00.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, May 7th. The company reported $3.79 EPS for the quarter, topping the consensus estimate of $3.55 by $0.24. The company had revenue of $3.60 billion during the quarter, compared to analyst estimates of $3.55 billion. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. The business’s revenue was down 2.0% on a year-over-year basis. During the same quarter last year, the firm earned $3.74 EPS. Equities analysts expect that Allergan plc will post 16.68 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Tuesday, May 14th will be given a dividend of $0.74 per share. The ex-dividend date is Monday, May 13th. This represents a $2.96 dividend on an annualized basis and a yield of 2.43%. Allergan’s dividend payout ratio is currently 17.74%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.